

Ting Niu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7937569/publications.pdf>

Version: 2024-02-01

99
papers

1,299
citations

430874

18
h-index

414414

32
g-index

103
all docs

103
docs citations

103
times ranked

2520
citing authors

#	ARTICLE	IF	CITATIONS
1	Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. <i>Nature</i> , 2016, 531, 471-475.	27.8	202
2	Potential role of exosome-associated microRNA panels and <i>in vivo</i> environment to predict drug resistance for patients with multiple myeloma. <i>Oncotarget</i> , 2016, 7, 30876-30891.	1.8	89
3	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1455-1470.	6.4	83
4	Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults. <i>Blood</i> , 2020, 135, 826-833.	1.4	74
5	A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia. <i>Frontiers in Pharmacology</i> , 2019, 10, 609.	3.5	60
6	Natural killer cell-based immunotherapy for acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2020, 13, 167.	17.0	55
7	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked <i>In Vitro</i> and <i>In Vivo</i> Antitumor Activities. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5488-5504.	6.4	53
8	Identification of 5-(2,3-Dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 11398-11414.	6.4	33
9	A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. <i>Journal of Hematology and Oncology</i> , 2021, 14, 37.	17.0	33
10	<i>In Vitro</i> and <i>In Vivo</i> Antitumor Activities of Tenacissoside C from <i>Marsdenia tenacissima</i> . <i>Planta Medica</i> , 2014, 80, 29-38.	1.3	31
11	Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	31
12	SKLB-677, an FLT3 and Wnt/ β -catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML. <i>Scientific Reports</i> , 2015, 5, 15646.	3.3	29
13	Anti-tumor activity and relative mechanism of ethanolic extract of <i>Marsdenia tenacissima</i> (Asclepiadaceae) against human hematologic neoplasm <i>in vitro</i> and <i>in vivo</i> . <i>Journal of Ethnopharmacology</i> , 2014, 153, 258-267.	4.1	28
14	Outcome of CARE: a 6-year national registry of acquired haemophilia A in China. <i>British Journal of Haematology</i> , 2019, 187, 653-665.	2.5	28
15	A multicenter, prospective evaluation of the Chinese Society of Thrombosis and Hemostasis Scoring System for disseminated intravascular coagulation. <i>Thrombosis Research</i> , 2019, 173, 131-140.	1.7	22
16	Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis. <i>European Journal of Medicinal Chemistry</i> , 2019, 169, 121-143.	5.5	21
17	SKLB-23bb, A HDAC6-Selective Inhibitor, Exhibits Superior and Broad-Spectrum Antitumor Activity via Additionally Targeting Microtubules. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 763-775.	4.1	19
18	Human DKK1 and human HSP70 fusion DNA vaccine induces an effective anti-tumor efficacy in murine multiple myeloma. <i>Oncotarget</i> , 2018, 9, 178-191.	1.8	19

#	ARTICLE	IF	CITATIONS
19	Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e699-e709.	0.4	19
20	Basiliximab for steroidâ€refractory acute graftâ€versusâ€host disease: A realâ€world analysis. <i>American Journal of Hematology</i> , 2022, 97, 458-469.	4.1	19
21	Evaluation of the new Chinese Disseminated Intravascular Coagulation Scoring System in critically ill patients: A multicenter prospective study. <i>Scientific Reports</i> , 2017, 7, 9057.	3.3	17
22	Epigenetic drug library screening identified an LSD1 inhibitor to target UTX-deficient cells for differentiation therapy. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 11.	17.1	17
23	Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2016, 9, 125.	17.0	16
24	BMI1 regulates multiple myeloma-associated macrophageâ€™s pro-myeloma functions. <i>Cell Death and Disease</i> , 2021, 12, 495.	6.3	16
25	Chimeric Antigen Receptor 4SCAR19-Modified T Cells in Acute Lymphoid Leukemia: a Phase II Multi-Center Clinical Trial in China. <i>Blood</i> , 2015, 126, 3774-3774.	1.4	16
26	Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails. <i>Frontiers in Pharmacology</i> , 2019, 10, 387.	3.5	15
27	An epigenetic mechanism underlying chromosome 17p deletion-driven tumorigenesis. <i>Cancer Discovery</i> , 2020, 11, CD-20-0336.	9.4	15
28	<i>SLC2A5</i> overexpression in childhood philadelphia chromosomeâ€positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2018, 183, 242-250.	2.5	14
29	Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of <i>BCR-ABL</i> -Induced B-Cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2019, 25, 7527-7539.	7.0	13
30	Firstâ€patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3053-3060.	3.8	13
31	Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , 2020, 11, 580622.	3.5	13
32	A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China. <i>Frontiers in Oncology</i> , 2021, 11, 750323.	2.8	12
33	Methotrexate-loaded biodegradable polymeric micelles for lymphoma therapy. <i>International Journal of Pharmaceutics</i> , 2019, 557, 74-85.	5.2	11
34	4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass. <i>Blood</i> , 2015, 126, 264-264.	1.4	10
35	Myocardial Injury in Multiple Myeloma Patients With Preserved Left Ventricular Ejection Fraction: Noninvasive Left Ventricular Pressure-Strain Myocardial Work. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 782580.	2.4	10
36	PIG7 promotes leukemia cell chemosensitivity via lysosomal membrane permeabilization. <i>Oncotarget</i> , 2016, 7, 4841-4859.	1.8	9

#	ARTICLE	IF	CITATIONS
37	Sustaining integrating imatinib and interferon- γ into maintenance therapy improves survival of patients with Philadelphia positive acute lymphoblastic leukemia ineligible for allogeneic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2016, 57, 2321-2329.	1.3	8
38	Estrogen-Responsive Gene MAST4 Regulates Myeloma Bone Disease. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 711-723.	2.8	8
39	Pathogenesis and treatment of multiple myeloma. <i>MedComm</i> , 2022, 3, .	7.2	8
40	Young female patients with multiple myeloma have low occurrence of osteolytic lesion. <i>Bone</i> , 2018, 110, 21-28.	2.9	6
41	Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age. <i>Platelets</i> , 2021, 32, 633-641.	2.3	6
42	Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China. <i>Journal of Cancer</i> , 2021, 12, 2633-2642.	2.5	6
43	Effect of Eltrombopag on Platelet Response and Safety Results in Chinese Adults with Chronic ITP-Primary Result of a Phase III Study. <i>Blood</i> , 2014, 124, 1464-1464.	1.4	6
44	Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension study. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 716-728.	3.8	6
45	ALCAM regulates multiple myeloma chemoresistant side population. <i>Cell Death and Disease</i> , 2022, 13, 136.	6.3	6
46	A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China. <i>International Journal of Hematology</i> , 2021, 113, 422-429.	1.6	5
47	Safety and Efficacy Analysis of Selinexor-Based Treatment in Multiple Myeloma, a Meta-Analysis Based on Prospective Clinical Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 758992.	3.5	5
48	Symptom clusters and quality of life in ambulatory patients with multiple myeloma. <i>Supportive Care in Cancer</i> , 2022, 30, 4961-4970.	2.2	5
49	Low-dose ruxolitinib shows effective in treating myelofibrosis. <i>Annals of Hematology</i> , 2021, 100, 135-141.	1.8	4
50	Intratumor Heterogeneity of MIF Expression Correlates With Extramedullary Involvement of Multiple Myeloma. <i>Frontiers in Oncology</i> , 2021, 11, 694331.	2.8	4
51	Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2022, 12, 37.	6.2	4
52	Epstein-Barr Virus-Positive Lymphoma-Associated Hemophagocytic Syndrome: A Retrospective, Single-Center Study of 51 Patients. <i>Frontiers in Immunology</i> , 2022, 13, 882589.	4.8	4
53	Clinical Characteristics and Risk Factors for Mortality in Cryptococcal Meningitis: Evidence From a Cohort Study. <i>Frontiers in Neurology</i> , 2022, 13, 779435.	2.4	4
54	Combination of FVIII and low-dose rFVIIa improves haemostasis in acquired haemophilia A patients: a collaborative controlled study. <i>Thrombosis Research</i> , 2015, 135, 835-840.	1.7	3

#	ARTICLE	IF	CITATIONS
55	A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models. <i>Oncotarget</i> , 2017, 8, 111495-111507.	1.8	3
56	Effectiveness and Tolerability of Micafungin in Chinese Patients with Invasive Fungal Infections: A Retrospective, Multicenter Study. <i>Advances in Therapy</i> , 2018, 35, 1400-1410.	2.9	3
57	Nanomedicine Applications in Treatment of Primary Central Nervous System Lymphoma: Current State of the Art. <i>Journal of Biomedical Nanotechnology</i> , 2021, 17, 1459-1485.	1.1	3
58	KMT2D Is a Haploinsufficient Tumor Suppressor in Acute Leukemia. <i>Blood</i> , 2018, 132, 1511-1511.	1.4	3
59	RIPK1 inhibition enhances the therapeutic efficacy of chidamide in FLT3-ITD positive AML, both <i>in vitro</i> and <i>in vivo</i> . <i>Leukemia and Lymphoma</i> , 2022, 63, 1167-1179.	1.3	3
60	Acute promyelocytic leukemia harbouring rare FLT3-TKD and WT1 mutations: A case report. <i>Oncology Letters</i> , 2015, 10, 1858-1862.	1.8	2
61	Predictive Values of PET/CT in Combination With Regulatory B Cells for Therapeutic Response and Survival in Contemporary Patients With Newly Diagnosed Multiple Myeloma. <i>Frontiers in Immunology</i> , 2021, 12, 671904.	4.8	2
62	Clinical Research On Hematological Malignancies Complicated With Active Tuberculosis:A Single Center Experience In China. <i>Blood</i> , 2013, 122, 5592-5592.	1.4	2
63	Rescue of a Terminally Ill Patient with Chemo-Refractory Acute Lymphoblastic Leukemia Carrying Bcr/Abl and TP53 Mutations Based on a 4th Generation CD19 Chimeric Antigen Receptor-Engineered T (CAR-T) Therapy. <i>Blood</i> , 2015, 126, 5431-5431.	1.4	2
64	Retrospective Treatment Analysis of a Series of 104 Patients with Adult Onset Hemophagocytic Lymphohistiocytosis in a Single Institution of China. <i>Blood</i> , 2016, 128, 4882-4882.	1.4	2
65	Inhibitory Effects of Liposomal Honokiol On the Lymphoma.. <i>Blood</i> , 2009, 114, 4788-4788.	1.4	2
66	Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2022, , .	2.2	2
67	Philadelphia chromosome with acute myeloid leukemia and concurrent large B cell lymphoma of different origins: A case report. <i>Oncology Letters</i> , 2017, 13, 1189-1193.	1.8	1
68	Clinical Research on Hematological Malignancies Complicated with dic-a Single Center Report in China. <i>Blood</i> , 2014, 124, 5062-5062.	1.4	1
69	Curcumin Potentiates Antitumor Activity of Imatinib Via Inhibition of the AKT/mTOR Signaling Pathway and Down-Regulation of Bcr-Abl Gene in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 3559-3559.	1.4	1
70	PTEN Regulated BCRP/ABCG2 and Side Population Through PI3K/Akt Pathway In Chronic Myeloid Leukemia. <i>Blood</i> , 2013, 122, 5408-5408.	1.4	1
71	Chidamide-Containing Conditioning Allogenic Hematopoietic Stem Cell Transplantation Improves Prognosis of Acute Lymphoblastic Leukemia with Pre-Transplant Response Less Than Complete Remission. <i>Blood</i> , 2018, 132, 3366-3366.	1.4	1
72	Methotrexate-Loaded Biodegradable Polymeric Micelles for Lymphoma Therapy in Mouse Model. <i>Blood</i> , 2018, 132, 4181-4181.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study. <i>Blood Advances</i> , 0, , .	5.2	1
74	Long Term Survival of Patients with Chronic Myelocytic Leukemia after Allogeneic Stem Cell Transplant Using a Reduced Intensity Regimen of Melphanlan, Lomustine and Cyclophosphamide.. <i>Blood</i> , 2005, 106, 5308-5308.	1.4	0
75	Immunotherapy with Recombinant Xenogeneic Vascular Endothelial Growth Factor as a Vaccine Combined Low-Dose Adriamycin Induces Synergistic Antitumor Efficacy in EL4 Lymphoma Model.. <i>Blood</i> , 2005, 106, 4811-4811.	1.4	0
76	Chronic Imatinib Mesylate Exposure Leads to Reduced Intracellular Drug Accumulation in K562 Cells Measured by High-Performance Liquid Chromatography.. <i>Blood</i> , 2005, 106, 4431-4431.	1.4	0
77	Outcome with Hyper-CVAD/MTX-Ara-C, a Dose-Intensive Regimen, in Acute Lymphocytic Leukemia and Highly Aggressive Lymphoma: A Preliminary Study in a Single Center in China.. <i>Blood</i> , 2006, 108, 4529-4529.	1.4	0
78	Outcome with Hyper-CVAD/MTX-Ara-C, a Dose-Intensive Regimen, in Acute Lymphocytic Leukemia and Highly Aggressive Lymphoma in China.. <i>Blood</i> , 2007, 110, 4328-4328.	1.4	0
79	Effect of Liposome Encapsulated Vesicular Stomatitis Virus Matrix Protein in Hematological Malignancy. <i>Blood</i> , 2008, 112, 4634-4634.	1.4	0
80	To Study the Proliferative Inhibition of Anticancer Drug in Two Kinds of Ph (+) Leukemia Cell Lines.. <i>Blood</i> , 2009, 114, 4110-4110.	1.4	0
81	Bone Marrow-Derived Mesenchymal Stem Cells Modified by Mouse Interferon- β Gene Reduce Fibrosis and Improve Function In a Mouse Model of Liver Fibrosis.. <i>Blood</i> , 2010, 116, 3768-3768.	1.4	0
82	Anti-Leukemia Effect of Rapamycin Alone or Plus Daunorubicin on Acute Lymphoblastic Leukemia Cell Lines. <i>Blood</i> , 2010, 116, 3256-3256.	1.4	0
83	The Transcription Factor SCL/TAL-1 Plays a Positive Role in the Erythropoietic Differentiation Via MEK/ERK Pathway in EPO-Induced K562 Cell Line. <i>Blood</i> , 2011, 118, 4799-4799.	1.4	0
84	Experience with Hemophagocytic Lymphohistiocytosis in Adults: A Retrospective Study of 56 Patients in a Single Institute of China. <i>Blood</i> , 2011, 118, 4727-4727.	1.4	0
85	An Escalated Dose of Bortezomib Plus Second Line Chemotherapy for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma,. <i>Blood</i> , 2011, 118, 3714-3714.	1.4	0
86	Treatment of Lymphoma in Mice by Intravenous Administration of Vesicular Stomatitis Virus Matrix Protein Gene Encapsulated in Cationic Liposome. <i>Blood</i> , 2011, 118, 4712-4712.	1.4	0
87	The Role of Transcription Factor SCL/TAL-1 in the Hematopoiesis of Human Cord Blood Hematopoietic Stem Cell. <i>Blood</i> , 2011, 118, 4795-4795.	1.4	0
88	MEK 1/2 Inhibitor UO126 Reversed Imatinib Resistance in IM-Resistant K562R. <i>Blood</i> , 2012, 120, 4914-4914.	1.4	0
89	Combination Imatinib with Interferon- β For Philadelphia Positive Acute Lymphocytic Leukemia: A Multiple Centers Study In China. <i>Blood</i> , 2013, 122, 5019-5019.	1.4	0
90	Decitabine Combined With Chemotherapy For The Treatment Of Refractory Acute Myeloid Leukemia: a Pilot Phase 1 Clinical Study. <i>Blood</i> , 2013, 122, 5001-5001.	1.4	0

#	ARTICLE	IF	CITATIONS
91	This Is a Title In Title Case: Safety and Efficacy of Intravenous 4.5g/m ² Methotrexate over 90 Minutes for Hematological Malignancy with Cerebral Involvement. <i>Blood</i> , 2013, 122, 5566-5566.	1.4	0
92	Immunosuppressive Treatment Combined with Nucleoside Analogues Is Superior to Nucleoside Analogues Alone in the Treatment of Severe Thrombocytopenia in Patients with Cirrhosis-Associated with Hepatitis B in China: A Multicenter, Observational Study. <i>Blood</i> , 2014, 124, 2778-2778.	1.4	0
93	Clinical Research on Burkitt Lymphoma—a Single-Center Report in China. <i>Blood</i> , 2014, 124, 5461-5461.	1.4	0
94	Construction of the Lentiviral and Electric Transfection Vectors Encoding Anti-Human CD30 or CD33 Chimeric Antigen Receptor (CAR) Gene and Respective Expression In Jurkat Leukemia Cell Line. <i>Blood</i> , 2014, 124, 5950-5950.	1.4	0
95	Alox15b Gene Contributes to Lymphoma Tumorigenesis Via PI3K/AKT/mTOR Pathway Activation and Has a Synergistic Effect with Alox5 Gene. <i>Blood</i> , 2018, 132, 4112-4112.	1.4	0
96	Identification and Characterization of EBV Genome in NKT Cell Lymphoma. <i>Blood</i> , 2018, 132, 5304-5304.	1.4	0
97	SLC2A5 Overexpression in Childhood Philadelphia Chromosome Positive Acute Lymphoblastic Leukaemia. <i>Blood</i> , 2018, 132, 5286-5286.	1.4	0
98	A Novel Hybrid Transplantation with Autologous Hematopoietic Stem Cells and Matched Unrelated Cord Blood Stem Cells Is Effective and Safe for Relapsed or Refractory Lymphoma: A Pilot Study. <i>Blood</i> , 2019, 134, 5713-5713.	1.4	0
99	Daratumumab, Bortezomib, Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory (RR) Multiple Myeloma (MM): Pooled Subgroup Analysis of Lepus and Castor. <i>Blood</i> , 2020, 136, 38-41.	1.4	0